Sugi Predict

Sugi Predict / Compounds / SCHEMBL6043379

SCHEMBL6043379

SCHEMBL6043379

COC1CCN(CCO)C1

nearest known ligand 0.37

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ SLC18A3 Q16572 1/20 0.37
▸ MAPK1 P28482 1/20 0.36
▸ LTA4H P09960 2/20 0.35
▸ GRIN1 Q05586 1/20 0.34
▸ GRIN2B Q13224 1/20 0.34
▸ ALDH1A1 P00352 3/20 0.34
▸ KDM4E B2RXH2 2/20 0.34
▸ GRM2 Q14416 1/20 0.32
▸ KIT P10721 1/20 0.32
▸ GBA1 P04062 1/20 0.32
▸ PKM P14618 1/20 0.31
▸ KMT2A Q03164 1/20 0.31
▸ SMN1; SMN2 Q16637 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15685469 1.00 SLC18A3 (0.37) SLC18A3MAPK1LTA4HGRIN1GRIN2B
SCHEMBL15685468 1.00 SLC18A3 (0.37) SLC18A3MAPK1LTA4HGRIN1GRIN2B
Hydrochloric Acid SCHEMBL25364283 0.98 SLC18A3 (0.36) SLC18A3MAPK1LTA4HGRIN1GRIN2B
SCHEMBL19617190 0.89 ALDH1A1 (0.40) MAPK1ALDH1A1KDM4ESMN1; SMN2
SCHEMBL19616664 0.89 GRIN1 (0.33) LTA4HGRIN1GRIN2BKMT2A
SCHEMBL12022452 0.89 ALDH1A1 (0.40) MAPK1ALDH1A1KDM4ESMN1; SMN2
SCHEMBL18159722 0.89 GRIN1 (0.33) LTA4HGRIN1GRIN2BKMT2A
SCHEMBL2114234 0.89 GRIN1 (0.33) LTA4HGRIN1GRIN2BKMT2A
SCHEMBL19617090 0.89 ALDH1A1 (0.40) MAPK1ALDH1A1KDM4ESMN1; SMN2
SCHEMBL4569263 0.88 SLC18A3 (0.43) SLC18A3ALDH1A1KDM4EPKMKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260085077-A1 HETEROCYCLIC DERIVATIVES AS JANUS KINASE INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2026-03-26 — — US disclosed
CN-111989321-B KRAS G12C inhibitors 米拉蒂治疗股份有限公司 2024-05-14 — — CN disclosed
US-20240101553-A1 KRAS G12C INHIBITORS MIRATI THERAPEUTICS INC (US) 2024-03-28 — — US disclosed
US-20230373999-A1 KRAS G12C INHIBITORS MIRATI THERAPEUTICS INC (US) 2023-11-23 — — US disclosed
US-20230373999-A1 KRAS G12C INHIBITORS MIRATI THERAPEUTICS INC (US) 2023-11-23 — — US disclosed
US-20230373999-A1 KRAS G12C INHIBITORS MIRATI THERAPEUTICS INC (US) 2023-11-23 — — US disclosed
CN-109843856-B KRAS G12C inhibitors 米拉蒂治疗股份有限公司 2023-05-02 — — CN disclosed
EP-3710439-B1 KRAS G12C INHIBITORS MIRATI THERAPEUTICS INC (US) 2023-02-15 — — EP disclosed
EP-3710439-B1 KRAS G12C INHIBITORS MIRATI THERAPEUTICS INC (US) 2023-02-15 — — EP disclosed
US-11267812-B2 KRAS G12C inhibitors Mirati Therapeutics, Inc. (US) 2022-03-08 — — US disclosed
US-20180072723-A1 KRAS G12C INHIBITORS Mirati Therapeutics, Inc. 2018-03-15 — — US disclosed
US-20180072723-A1 KRAS G12C INHIBITORS Mirati Therapeutics, Inc. 2018-03-15 — — US disclosed
WO-2017155910-A1 THIAZOLIDINONE COMPOUNDS AND USE THEREOF NATIONAL HEALTH RESEARCH INSTITUTES (TW) 2017-09-14 — — WO disclosed
US-20080274107-A1 Tyrosine kinase inhibitors MERCK SHARP & DOHME CORP. 2008-11-06 — — US disclosed
US-20080274107-A1 Tyrosine kinase inhibitors MERCK SHARP & DOHME CORP. 2008-11-06 — — US disclosed
US-7186723-B2 Tyrosine kinase inhibitors MERCK & CO., INC. (US) 2007-03-06 — — US disclosed
US-7186723-B2 Tyrosine kinase inhibitors MERCK & CO., INC. (US) 2007-03-06 — — US disclosed
US-20060089355-A1 Methods of treating alzheimer's disease using aromatically substituted w-amino-alkanoic acid amides and alkanoic acid diamides ELAN PHARMACEUTICALS, INC. 2006-04-27 — — US disclosed
US-5641778-A EXHIBIT RENIN-INHIBITING PROPERTIES AND CAN BE USED AS ANTIHYPERTENSIVE AGENTS CIBA-GEIGY CORPORATION (US) 1997-06-24 — — US disclosed
EP-0716077-A1 Aromatically substituted omega amino alcanoic acid amides and alcanoic diamides and their use as renine inhibitors CIBA-GEIGY AG (CH) 1996-06-12 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11267812-B2 KRAS G12C inhibitors KRAS, NRAS, HRAS SLC18A3 4800/4885MAPK1 310/4885LTA4H 3802/4885
US-20060089355-A1 Methods of treating alzheimer's disease using aromatically substituted w-amino-alkanoic acid amides and alkanoic acid diamides APP, BACE1, BACE2 SLC18A3 579/4885MAPK1 3638/4885LTA4H 900/4885
US-20260085077-A1 HETEROCYCLIC DERIVATIVES AS JANUS KINASE INHIBITORS TYK2, JAK1, JAK3 SLC18A3 4814/4885MAPK1 150/4885LTA4H 1335/4885
US-20240101553-A1 KRAS G12C INHIBITORS KRAS, NRAS, HRAS SLC18A3 4800/4885MAPK1 310/4885LTA4H 3802/4885
US-20180072723-A1 KRAS G12C INHIBITORS KRAS, NRAS, HRAS SLC18A3 4800/4885MAPK1 310/4885LTA4H 3802/4885
US-20080274107-A1 Tyrosine kinase inhibitors ERBB2, TYRO3, TIE1 SLC18A3 4815/4885MAPK1 67/4885LTA4H 2017/4885
US-20230373999-A1 KRAS G12C INHIBITORS KRAS, NRAS, HRAS SLC18A3 4800/4885MAPK1 310/4885LTA4H 3802/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.